Trial Profile

Phase I PKPD study of Lanifibranor in Japanese patients

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lanifibranor (Primary)
Indications Non-alcoholic steatohepatitis
Focus Pharmacodynamics; Pharmacokinetics

Most Recent Events

20 Feb 2025 According to Inventiva media release, 32 subjects will be separated randomly into four cohorts and will receive lanifibranor once daily for 14 days.
20 Feb 2025 According to Inventiva media release, first patient has been dosed in this study.
20 Feb 2025 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com